Journal of Pharmacology and Pharmacotherapeutics

MOLECULES OF THE MILLENNIUM
Year
: 2012  |  Volume : 3  |  Issue : 4  |  Page : 353--355

Istaroxime: A rising star in acute heart failure


Suruchi Aditya1, Aditya Rattan2 
1 Department of Pharmacology, Dr Harvansh Singh Judge Institute of Dental Sciences, Chandigarh, Punjab, India
2 Department of Cardiology, Heartline, Panchkula, Haryana, India

Correspondence Address:
Suruchi Aditya
Department of Pharmacology, Dr Harvansh Singh Judge Institute of Dental Sciences, Chandigarh, Punjab
India

Heart failure in India is a growing epidemic. Around 30 to 40% of patients die from heart failure within one year of receiving the diagnosis. Currently available inotropes have not only failed to show consistent results but are also associated with adverse outcomes. Istaroxime is a novel intravenous agent with luso-inotropic properties that acts by inhibition of Na + /K + adenosine triphosphatase and stimulation of sarco/ endoplasmic reticulum calcium ATPase isoform 2. In clinical studies, it significantly decreased left ventricular end diastolic pressure, pulmonary capillary wedge pressure, heart rate and increased systolic blood pressure and cardiac index with no change in neurohormones, renal function or troponin I. Istaroxime is a promising alternative for patients presenting with acute heart failure syndrome for whom the therapeutic options are currently limited.


How to cite this article:
Aditya S, Rattan A. Istaroxime: A rising star in acute heart failure.J Pharmacol Pharmacother 2012;3:353-355


How to cite this URL:
Aditya S, Rattan A. Istaroxime: A rising star in acute heart failure. J Pharmacol Pharmacother [serial online] 2012 [cited 2020 Oct 28 ];3:353-355
Available from: http://www.jpharmacol.com/article.asp?issn=0976-500X;year=2012;volume=3;issue=4;spage=353;epage=355;aulast=Aditya;type=0